Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 102, Issue 4, Pages 693-703
Publisher
Springer Nature
Online
2010-02-10
DOI
10.1038/sj.bjc.6605534
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
- (2009) Winder ONCOLOGY REPORTS
- Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
- (2009) J. Yun et al. SCIENCE
- High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
- (2008) J. W. Tyner et al. BLOOD
- Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
- (2008) Véronique Gelsi-Boyer et al. BMC CANCER
- Dual-specificity MAP kinase phosphatases (MKPs) and cancer
- (2008) Stephen M. Keyse CANCER AND METASTASIS REVIEWS
- K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy
- (2008) M.-C. Etienne-Grimaldi et al. CLINICAL CANCER RESEARCH
- Understanding the Predictive Role of K-ras for Epidermal Growth Factor Receptor–Targeted Therapies in Colorectal Cancer
- (2008) Francisco Javier Ramos et al. Clinical Colorectal Cancer
- Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
- (2008) Daniel J. Freeman et al. Clinical Colorectal Cancer
- ras oncogenes: their role in neoplasia
- (2008) M. BARBACID EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- K-Ras Mutations Are Changing Practice in Advanced Colorectal Cancer
- (2008) Caroline McNeil JNCI-Journal of the National Cancer Institute
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Setting future standards for KRAS testing in colorectal cancer
- (2008) Han van Krieken et al. PHARMACOGENOMICS
- Mutation analysis in Costello syndrome: functional and structural characterization of theHRASp.Lys117Arg mutation
- (2007) Ellen Denayer et al. HUMAN MUTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now